BmKn-2 scorpion venom peptide for killing oral cancer cells by apoptosis

Pirut Tong-ngam1, Sittiruk Roytrakul, Hathaitip Sritanaudomchai

  • 1Institute of Molecular Biosciences, Nakhon Pathom, Thailand

Insights

Scorpion venom peptide BmKn-2 shows potent anticancer activity against oral cancer cells by inducing apoptosis. This peptide offers a promising alternative to conventional chemotherapy, bypassing drug resistance mechanisms.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Scorpion venom peptides are emerging as novel chemotherapeutic agents.
  • They offer specific cytotoxicity and can overcome multidrug resistance.
  • Potential for combination therapy and improved safety profiles exist.

Purpose of the Study:

  • To assess the anticancer activities of the BmKn-2 scorpion venom peptide and its derivatives.
  • To evaluate the efficacy of BmKn-2 against human oral squamous cell carcinoma (HSC-4).

Main Methods:

  • Screening assays to identify effective peptides.
  • In vitro studies using the HSC-4 cell line.
  • Phase contrast microscopy and Reverse Transcription Polymerase Chain Reaction (RT-PCR) to analyze apoptosis.

Main Results:

  • BmKn-2 demonstrated significant cytotoxicity against HSC-4 cells with an IC50 of 29 μg/ml.
  • Apoptosis induction in HSC-4 cells was confirmed by morphological changes and RT-PCR.
  • Increased expression of pro-apoptotic genes (caspase-3, -7, -9) and decreased BCL-2 mRNA levels were observed.

Conclusions:

  • BmKn-2 scorpion venom peptide exhibits specific membrane binding, growth inhibition, and apoptogenic activity against human oral cancer cells.
  • BmKn-2 represents a potential therapeutic candidate for oral cancer treatment.

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.7K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K